Skip to content
Checking whether you are signed in

Tempus AI, Inc.

TEMNasdaqFull coverage

Price
Loading your watchlists

Latest dossier

AI-generated

General research and analysis by Moatsight, not personalized investment advice. We show, you decide. Disclaimers

How dossiers are written

Q3 of fiscal year 2026 · Published Nov 7, 2026, 8:07 PM UTC

Tempus AI runs cancer and hereditary genetic testing laboratories and licenses the de-identified data they produce to drug companies, with AI applications still a small part of revenue. In the third quarter of fiscal 2026 revenue grew 23.1% to $411.5 million and the company raised its full-year guidance for the third time, while data revenue from customers not related to the founder grew fast but growth in Insights, the core licensing product, slowed for the third quarter running. The smaller net loss came mainly from gains on shares Tempus holds, and the operating loss, after stock-based compensation of 11.7% of revenue, barely changed. Moatsight estimates revenue of $1,920.3 million over the four quarters to the third quarter of fiscal 2027, including the pending Personalis purchase, and expects GAAP losses to continue over that period.

Read the dossier

What you pay

FigureAt the close5-yr median5-yr range
P/ENo value: no close yetNo value: no price history
EV/SalesNo value: no close yetNo value: no price history
EV/EBITDANo value: no close yetNo value: no price history
Price/FCFNo value: no close yetNo value: no price history
Market capNo value: no close yet
Net debt and other claims(enterprise value minus market cap)No value: no close yet
Enterprise valueNo value: no close yet

How the business is doing

FigureLast 12 months1-year change1-yearYearly, 3 years8 quarters
Revenue$1.5B+36.6%(better for the company)No value: history too shortEach quarter is listed in the row's details.
Diluted EPSNo value: cannot be derivedNo value: cannot be derivedNo value: cannot be derivedEach quarter is listed in the row's details.
Free cash flow−$150.6Mn/m, not meaningful: from zero or belowNo value: history too shortEach quarter is listed in the row's details.
Gross marginNo value: not in the filingsNo value: not in the filingsNo value: not in the filingsNo value: not in the filings
Operating margin−18.5%+3.4 pp(better for the company)No value: history too shortEach quarter is listed in the row's details.
Net margin−12.5%+5.9 pp(better for the company)No value: history too shortEach quarter is listed in the row's details.
Share count181.311M+3.6%(worse for the company)No value: history too shortEach quarter is listed in the row's details.
How to read these figures
  • Last 12 months: the latest four reported quarters added up, or a figure computed from them. The share count is its latest quarter's average.
  • 1-year change: the last 12 months against the 12 months a year earlier. A margin's change is in percentage points (pp). On a Next 12 months row, it is Moatsight's estimate against the last 12 months.
  • Yearly, 3 years: the yearly rate over the last 3 years, compounded. For a margin, its average change a year in percentage points.
  • 8 quarters: the last 12 months at each of the latest 8 quarter ends, oldest on the left; the dot is the latest. The quarters themselves are on Financials.
  • n/m: not meaningful, such as a rate of change from a loss.
  • Color: a 1-year change in the gain color is better for the company, one in the loss color worse. The caret and the sign show which way it moved, and a row where lower is better says so in its details. Color judges the company's reported results, never its share price or Moatsight's estimates, and no other column is colored.

Price

No closing prices are stored for this listing yet.

Facts

Exchange
Nasdaq · USD
Kind
Common stock
Security
Common Stock